Our Network

AstraZeneca and Daiichi Sankyo’s Enhertu showed a median progression-free survival of 6.9 months and median overall survival of 13.4 months in the overall trial population.
Results reaffirm potential role of Enhertu as a tumour-agnostic therapy for previously treated patients with HER2-expressing solid tumours and support ongoing discussions with global regulatory authorities.

AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan plus Imfinzi showed a confirmed objective response rate of 79%. Two ongoing Phase III trials are evaluating datopotamab deruxtecan in patients with triple-negative breast cancer.

Transthyretin amyloidosis (ATTR) remains an underdiagnosed and underrecognised disease despite several guidelines available that inform its diagnosis and care. ATTR, which can show up in different forms, and its symptoms are commonly misattributed to other conditions. Patients with ATTR need a timely diagnosis and specialised plan to slow disease progression and improve their quality of life.

59% of these patients treated with Tagrisso plus chemotherapy had complete brain tumour responses in FLAURA2 Phase III trial.

Imfinzi reduced the risk of disease progression or death by 29% vs. chemotherapy. First Phase III trial to demonstrate clinical benefit of immunotherapy plus PARP inhibition in advanced or recurrent endometrial cancer.

Trial will continue to assess primary endpoint of event-free survival.

Approval exemplifies commitment to broadening access for patients living with rare diseases globally.

At AstraZeneca, we have the ambition to redefine the backbone of current cancer treatment – chemotherapy and radiotherapy regimens – with our discovery platform that delivers highly targeted antibody-drug conjugates (ADCs) and radioconjugates directly into cancer cells.

Decision based on FLAURA2 Phase III trial results which extended median progression-free survival by nearly 9 months versus standard of care.

Data covering almost 30 million individuals show continued burden of disease;
immunocompromised individuals comprise approximately one quarter of all COVID-19
hospitalisations, ICU admissions and deaths.